Xeris Biopharma
(NASDAQ) XERS
Xeris Biopharma Financials at a Glance
Market Cap
$1.04B
Revenue (TTM)
$291.85M
Net Income (TTM)
$554.00K
EPS (TTM)
$-0.01
P/E Ratio
-805.33
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Price
$6.03
Volume
28,861
Open
$5.93
Price
$6.03
Volume
28,861
Open
$5.93
Previous Close
$6.03
Daily Range
$5.88 - $6.13
52-Week Range
$3.81 - $10.08
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Price
$6.03
Volume
28,861
Open
$5.93
Previous Close
$6.03
Daily Range
$5.88 - $6.13
52-Week Range
$3.81 - $10.08
XERS News
XERS: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Xeris Biopharma
Industry
Pharmaceuticals
Sector
Health CareEmployees
435
CEO
John Patrick Shannon, Jr.
Website
www.xerispharma.comHeadquarters
Chicago, IL 60601, US
XERS Financials
Key Financial Metrics (TTM)
Gross Margin
82%
Operating Margin
9%
Net Income Margin
0%
Return on Equity
0%
Return on Capital
9%
Return on Assets
0%
Earnings Yield
-0.12%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.04B
Shares Outstanding
172.43M
Volume
28.86K
Short Interest
0.00%
Avg. Volume
2.01M
Financials (TTM)
Gross Profit
$238.43M
Operating Income
$24.90M
EBITDA
$12.71M
Operating Cash Flow
$28.63M
Capital Expenditure
$696.00K
Free Cash Flow
$27.93M
Cash & ST Invst.
$111.04M
Total Debt
$37.76M
Xeris Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$85.81M
+42.8%
Gross Profit
$66.73M
+31.8%
Gross Margin
77.77%
N/A
Market Cap
$1.04B
N/A
Market Cap/Employee
$2.64M
N/A
Employees
394
N/A
Net Income
$11.08M
+316.7%
EBITDA
$14.13M
+146.8%
Quarterly Fundamentals
Net Cash
$73.28M
+136.7%
Accounts Receivable
$51.05M
+26.3%
Inventory
$68.67M
+42.5%
Long Term Debt
$31.53M
-87.4%
Short Term Debt
$6.23M
-70.6%
Return on Assets
0.14%
N/A
Return on Invested Capital
9.09%
N/A
Free Cash Flow
$19.71M
+1023.1%
Operating Cash Flow
$20.04M
+914.8%